Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZK-283197
- Development stage
- Phase 2
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ZK-283197 is a selective and orally active estrogen receptor beta (ERβ) agonist that was under development by Bayer Healthcare for the treatment of vasomotor symptoms, particularly hot flushes in postmenopausal women. The drug is a small molecule that acts specifically on ERβ, distinguishing it from non-selective estrogen therapies. Its primary indication was menopausal vasomotor symptoms, and clinical investigations focused on efficacy and safety compared to standard estradiol treatment. Development was terminated after completion of phase II trials in 2014.
- Other names
- ZK-283197ZK283197ZK 283197BAY 86-5310BAY86-5310BAY-86-5310SH-T04211CSH-T-04211CSH-T 04211C
02
Targets
ESR2 (ERβ)
Beyond the preview
Go deeper on ZK-283197.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZK-283197.